Schizophrenia Research
Volume 86, Issue 1 , Pages 45-53 , September 2006

Evidence that brain tissue volumes are associated with HVA reactivity to metabolic stress in schizophrenia

  • Machteld Marcelis

      Affiliations

    • Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University, PO Box 616 (VIJV1), 6200 MD Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 43 3688679/666; fax: +31 43 3688689.
    • ,
  • John Suckling

      Affiliations

    • Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
    • ,
  • Paul Hofman

      Affiliations

    • Department of Radiology, University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Peter Woodruff

      Affiliations

    • Department of Psychiatry, Sheffield Cognition and Neuroimaging Laboratory, Academic Clinical Psychiatry, University of Sheffield, The Longley Centre, Norwood Grange Drive, Sheffield, S5 7JT, UK
    • ,
  • Ed Bullmore

      Affiliations

    • Department of Psychiatry, University of Cambridge, UK
    • ,
  • Jim van Os

      Affiliations

    • Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University, PO Box 616 (VIJV1), 6200 MD Maastricht, The Netherlands
    • Division of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK

Received 27 July 2005 ,Revised 1 May 2006 ,Accepted 2 May 2006.

References 

  1. Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulo V, et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol. Psychiatry. 2004;55:1001–1006
  2. Adler CM, Elman I, Weisenfeld N, Kestler L, Pickar D, Breier A. Effects of acute metabolic stress on striatal dopamine release in healthy volunteers. Neuropsychopharmacology. 2000;22(5):545–550
  3. Amin F, Davidson M, Davis KL. Homovanillic acid measurement in clinical research: a review of methodology. Schizophr. Bull. 1992;18(1):123–148
  4. Breier A. A.E. Bennett award paper. Experimental approaches to human stress research: assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients. Biol. Psychiatry. 1989;26(5):438–462
  5. Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch. Gen. Psychiatry. 1992;49:921–926
  6. Breier A, Davis O, Buchanan R, Listwak SJ, Holmes C, Pickar D, et al. Effects of alprazolam on pituitary–adrenal and catecholaminergic responses to metabolic stress in humans. Biol. Psychiatry. 1992;32(10):880–890
  7. Breier A, Crane AM, Kennedy C, Sokoloff L. The effects of pharmacologic doses of 2-deoxy-d-glucose on local cerebral blood flow in the awake, unrestrained rat. Brain Res. 1993;618(2):277–282
  8. Breier A, Davis OR, Buchanan RW, Moricle LA, Munson RC. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume. Arch. Gen. Psychiatry. 1993;50(7):541–550
  9. Burns J, Job D, Bastin ME, Whalley H, Macgillivray T, Johnstone EC, et al. Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study. Br. J. Psychiatry. 2003;182:439–443
  10. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry. 1991;148:1474–1486
  11. Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, et al. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology. 2005;30(4):765–774
  12. Deutch AY, Clark WA, Roth RH. Prefrontal cortical dopamine depletion enhances the responsiveness of the mesolimbic dopamine neurons to stress. Brain Res. 1990;521(1–2):311–315
  13. Elman I, Sokoloff L, Adler CM, Weisenfeld N, Breier A. The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers. Brain Res. 1999;815(2):243–249
  14. Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome?. Clin. Neurosci. 1995;3(2):89–97
  15. Glenthoj BY. The brain dopaminergic system. Pharmacological, behavioural and electrophysiological studies. Dan. Med. Bull. 1995;42:1–21
  16. Goldstein H. Multilevel Models in Educational and Social Research. London: Griffin; 1987;
  17. Hegarty AA, Vogel WH. The effect of acute and chronic diazepam treatment on stress-induced changes in cortical dopamine in the rat. Pharmacol. Biochem. Behav. 1995;52(4):771–778
  18. Heinz A, Romero B, Gallinat J, Juckel G, Weinberger DR. Molecular brain imaging and the neurobiology and genetics of schizophrenia. Pharmacopsychiatry. 2003;36(Suppl 3):S152–S157
  19. Hubl D, Koenig T, Strik W, Federspiel A, Kreis R, Boesch C, et al. Pathways that make voices: white matter changes in auditory hallucinations. Arch. Gen. Psychiatry. 2004;61(7):658–668
  20. Hulshoff Pol HE, Schnack HG, Mandl RCW, Cahn W, Collins DL, Evans AC, et al. Focal white matter density changes in schizophrenia: reduced inter-hemispheric connectivity. Neuroimage. 2004;21:27–35
  21. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry. 2003;160:13–23
  22. Kapur S, Lecrubier Y. Dopamine in the Pathophysiology and Treatment of Schizophrenia—New Findings. London, United Kingdom: Martin Dunitz-Taylor & Francis Group; 2003;
  23. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13(2):261–276
  24. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988;23(1):99–110
  25. Kopin IJ, Bankiewicz KS, Harvey-White J. Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: validation in monkeys treated with MPTP. Neuropsychopharmacology. 1988;1(2):119–125
  26. Kubicki M, Westin C, Nestor PG, Wible CG, Frumin M, Maier SE, et al. Cingulate fasciculus integrity disruption in schizophrenia: a magnetic resonance diffusion tensor imaging study. Biol. Psychiatry. 2003;54:1171–1180
  27. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Res. Rev. 2000;31:371–384
  28. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 1999;13:358–371
  29. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry. 2005;62:361–370
  30. Lukoff D, Nuechterlein KH, Ventura J. Manual for the Expanded Brief Psychiatric Rating Scale. Schizophr. Bull. 1986;12:594–602
  31. Marcelis M, Myin-Germeys I, Suckling J, Woodruff P, Hofman P, Bullmore E, et al. Cerebral tissue alterations and daily life experience in psychosis. Acta Psychiatr. Scand. 2003;107:54–59
  32. Marcelis M, Suckling J, Woodruff P, Hofman P, Bullmore E, Van Os J. Searching for a structural endophenotype in psychosis using computational morphometry. Psychiatry Res. Neuroimaging. 2003;122:153–167
  33. Marcelis M, Cavalier E, Gielen J, Delespaul Ph, Van Os J. Abnormal response to metabolic stress in schizophrenia: marker of vulnerability or acquired sensitization?. Psychol. Med. 2004;34(6):1103–1111
  34. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system [news]. Arch. Gen. Psychiatry. 1991;48(8):764–770
  35. Mitropoulou V, Goodman M, Sevy S, Elman I, New AS, Iskander EG, et al. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizotypal personality disorder. Schizophr. Res. 2004;70(1):27–31
  36. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962;10:779–812
  37. Smeets R, Dingemans P. Composite International Diagnostic Interview (CIDI). World Health Organization; 1993;
  38. Spitzer RL, Endicott J, Robbins E. Research Diagnostic Criteria (RDC) for a Selected Group of Functional Psychoses. New York: Biometrics Research Division, New York State Psychiatric Institute; 1978;
  39. StataCorp, 2001. STATA Statistical Software: Release 8.0. College Station, Texas.
  40. Suckling J, Brammer MJ, Lingford-Hughes A, Bullmore ET. Removal of extracerebral tissues in dual-echo magnetic resonance images via linear scale-space features. Magn. Reson. Imaging. 1999;17:247–256
  41. Suckling J, Sigmundsson T, Greenwood K, Bullmore ET. A modified fuzzy clustering algorithm for operator independent brain tissue classification of dual echo MR images. Magn. Reson. Imaging. 1999;17:1065–1076
  42. Vermetten E, Bremner JD. Circuits and systems in stress: I. Preclinical studies. Depress. Anxiety. 2002;15:126–147
  43. Weinberger DR, Lipka BK. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr. Res. 1995;16:87–110
  44. WHO . WHO Coordinated Multicenter Study on the Course and Outcome of Schizophrenia. Geneva: World Health Organisation; 1992;
  45. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry. 2000;157(1):16–25
  46. Zhou S, Suzuki M, Hagino H, Takahashi T, Kawasaki Y, Nohara S, et al. Decreased volume and increased asymmetry of the anterior limb of the internal capsule in patients with schizophrenia. Biol. Psychiatry. 2003;54:427–436

PII: S0920-9964(06)00225-8

doi: 10.1016/j.schres.2006.05.001

Schizophrenia Research
Volume 86, Issue 1 , Pages 45-53 , September 2006

Article Tools

* Image Usage & Resolution